Compare Moderna, Inc. (MRNA) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance

Moderna, Inc.Trade

Invesco NASDAQ 100 ETFTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs Invesco NASDAQ 100 ETF — how do they compare? Moderna, Inc. trades at $137.1 (market cap $54.14B), while Invesco NASDAQ 100 ETF trades at $294.43. Which is the better fit depends on your goals.

	MRNA	QQQM
Market Cap	$54.14B	—
Sector	Health	Broad Market / Factor
52-Week High	$174.38	$307.23
52-Week Low	$22.36	$229.87
Enterprise Value	$50.29B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.

The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.

Invesco NASDAQ 100 ETF

QQQM trades at $295.76, down 0.1% with a bullish technical signal from moving averages. The ETF tracks the Nasdaq-100 index, offering diversified exposure to large-cap growth stocks. Recent news highlights QQQM's low expense ratio advantage over QQQ and its position as a core growth allocation option for investors seeking Nasdaq-100 exposure.

The outlook remains positive for long-term growth investors, with technical indicators supporting bullish momentum. Key risks include concentration in top holdings and market sensitivity to technology sector performance. The ETF's low-cost structure provides a competitive advantage for sustained investment.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRNA

View details →

QQQM

TQQQ returned 59.18% vs. QQQ's 24.99%, but leverage costs and daily resets reduce its triple return over time.24/7 Wall Street · 16 hours agoNeutral SCHG preferred over QQQM for broader growth exposure and lower cost, while QQQM suits pure Nasdaq-100 focus.Seeking Alpha · 23 hours agoBullish QQQM ETF offers lower fees than QQQ, saving investors thousands over decades with identical Nasdaq-100 exposure.24/7 Wall Street · 1 day agoNeutral View details →

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

About Invesco NASDAQ 100 ETF

QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.